肾康注射液治疗早期糖尿病肾病的Meta分析  

Treatment of early diabetic nephropathy with Shenkang injection: a Meta-analysis

作　　者：宁泽琼 乔逸[2] 白娟[2] 王婧雯[2] 黄晓峰[1] 赵先[2] 徐焕春[2] 文爱东[2] 

机构地区：[1]陕西中医学院药学院,陕西咸阳712046 [2]第四军医大学西京医院药剂科,陕西西安710032

出　　处：《陕西中医学院学报》2014年第6期39-43,共5页Journal of Shaanxi College of Traditional Chinese Medicine

基　　金：国家863课题(编号:2012AA02A603)

摘　　要：目的评价肾康注射液(Shenkang injection,SKI)治疗早期糖尿病肾病(Early diabetic nephropathy,EDN)的有效性和安全性。方法遵循循证医学要求,计算机检索Pub Med、Medline、Embase、Cochrane Library、万方数字化期刊全文数据库、中国期刊全文数据库(CNKI)及中国科技期刊数据库(VIP),搜索有关SKI治疗EDN的随机对照试验。采用Review Manager5.1软件,对符合纳入标准文献进行Meta分析。结果共纳入文献7篇,430例患者。Meta分析结果显示,实验组用SKI治疗后显效率(OR=2.52,95%CI=1.18~5.40,P=0.02)和总有效率(OR=3.33,95%CI=1.61~6.89,P=0.001)优于对照组,降低患者24 h尿白蛋白定量(MD=-30.42,95%CI=-36.32^-24.52,P=0.000)、血清肌酐(MD=-17.35,95%CI=-32.13^-2.56,P=0.02)及血清尿素氮(MD=-1.26,95%CI=-1.64^-0.88,P=0.000)水平均优于对照组。纳入文献均无不良反应报告。结论SKI治疗EDN的总有效率和显效率均较对照组高,不良反应发生较少。说明SKI对于治疗EDN有效,但因纳入研究的样本量小且质量低,所以上述结论需更多的大样本随机对照试验来证实。ObjectiveTo evaluate the effects and safety of Shenkang injection（SKI） in the treatment of early diabetic nephropathy（EDN）. Method Follow the requirements of evidence - based medicine, databases of PubMed, Medline, Embase, Cochrane Library, Wanfang digital journals, CNKI and VIP were searched. Randomized controlled trials about SKI treatment of EDN were included. The Review Manager 5.1 softwar was used for Meta analysis. Results 7 studies in= volving 430 patients were included. The Meta analysis indicated that the effectiveness of SKI was significantly higher than that of control grop in effective rate（ OR =2.52,95 % CI = 1.18 -5.40, P = 0.02）, total effective rate（ OR = 3.33, 95 %CI=1.61-6.89, P=0. 001）, UAER（MD = -30.42, 95 %CI= -36.32- -24.52, P =0.000）, Scr（MD = - 17.35, 95 %CI= -32.13 - -2.56, P=0. 02）and BUN（MD = -1.26, 95 %CI= -1.64 - -0.88, P =0.000）lev- els in EDN patients. There is no oceured adverse events. CondusionSKI is more efficient in treatment of EDN and decrease UAER significantly than control group. It appears to be safe. Nevertheless, as the evidence obtained in this survey is not robust due to the poor quality of current studies, so the conclusions need more large-scale RCTs to confirm.

关 键 词：肾康注射液 早期糖尿病肾病 META分析 

分 类 号：R587.2[医药卫生—内分泌]